Explore

Companies

Drugs

/

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Oncology/Rectal Cancer

Rectal Cancer

103

Pipeline Programs↗

225

Active Trials↗

43

Companies Involved↗

Rectal Cancer is a highly competitive landscape with 103 programs across 43 companies. 35 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

80/100

Pipeline Velocity

77/100

Mech. Concentration

19/100

Completion Rate

75/100

Attrition Rate

9/100

Pipeline

Programs by Phase

Preclinical7

HA35

Nakhia Impex LLC

Total Neoadjuvant Therapy

St. James's Hospital, Ireland

Raltitrexed

Nanjing Chia-tai Tianqing Pharmaceutical

Therapeutic Target Tailored Chemotherapy

Grupo Hospital de Madrid

Iparomlimab

Tianjin Medical University Cancer Institute and Hospital

Phase 17

PD-1 Blocking Antibody

Sun Yat-sen University

Consolidation Therapy

Institute of Hematology & Blood Diseases Hospital, China

Papaverine

Western Galilee Hospital-Nahariya

Copper Cu-64-DOTA-Alendronate

City of Hope Medical Center

Imfinzi

University Medical Center Groningen

Phase 254

Liposomal Irinotecan

Astellas

Etrumadenant

Arcus Biosciences

Zimberelimab

Arcus Biosciences

Ivonescimab

Summit Therapeutics

Drug：sintilimab

Sun Yat-sen University

Phase 335

Envafolimab

Tracon Pharmaceuticals Inc.

Adjuvant Chemotherapy

Nizhny Novgorod Regional Clinical Oncology Center

Leucovorin

Glaxo Dba Glaxosmithkline

PD-1 Antibody

Sir Run Run Shaw Hospital

Capecitabine

Engelhard Arzneimittel GmbH & Co.KG

Approved

No programs

Analysis

Modality Breakdown

71%

Small molecule

65 of 92 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 92 classified programs, each share of the total. Modality classified for 92% of 103 pipeline programs.

Analysis

Trial Status

447

clinical trials

Completed121 · 27%

Recruiting117 · 26%

Unknown status60 · 13%

Not yet recruiting56 · 13%

Active, not recruiting51 · 11%

Terminated26 · 6%

Other16 · 4%

Clinical Trials

Trial Activity

447 trials

A Phase I Study of the Safety and Efficacy of a Modified Vaccinia Virus (BT-001) Delivered by Endoscopic Intra-tumoural Injection Followed by Systemic Antiprogammed Death-1 (Anti-PD-1) Antibodies in Patients With Localised Rectal Cancer With Proficient Mismatch Repair (pMMR)

Recruiting·—·Phase 1·NCT07687875·20 enrolled

A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04165772·212 enrolled

A Phase 2 Single-arm Study of Cemiplimab, Added to Typical Chemotherapy (Gemcitabine, Cisplatin, Nab-paclitaxel) for Down-staging of Locally Advanced, Unresectable Biliary Tract Cancer

Recruiting·CColumbia University·Phase 2·NCT07433673·20 enrolled

ABCSG R07 Rectal Cancer Registry (RCR) - Multicenter Retrospective and Prospective Analysis of Patients With Localized, Non-metastatic Rectal Cancer in Austria

Recruiting·AAustrian Breast & Colorectal Cancer Study Group·N/A·NCT07780305·600 enrolled

Pilot Evaluation of the Immunogenic Potentiation of Neo-adjuvant Brachytherapy Followed by Nivolumab Immunotherapy Without Chemotherapy in Stage II/III Locally Advanced Mismatch Repair Proficient Rectal Cancer

Recruiting·—·Phase 2·NCT07645118·10 enrolled

MEND-IT II: Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer.

Recruiting·JJ. W. A. Burger·Phase 3·NCT07472868·394 enrolled

Neoadjuvant Chemotherapy Plus Serplulimab Before Versus After Short-Course Radiotherapy in Locally Advanced Rectal Cancer : A Multicenter, Randomized Phase II Study With Integrated Multi-omics Profiling (NeoCSR-Omics Trial)

Recruiting·CChongqing University Cancer Hospital·Phase 2·NCT07898865·100 enrolled

68Ga FAPI in Total Neoadjuvant Therapy of Rectal Cancer

Recruiting·CChang Gung Memorial Hospital·N/A·NCT06157463·99 enrolled

Short-Course Radiotherapy Followed by Fruquintinib Plus Tislelizumab and CAPOX Versus Short-Course Radiotherapy Followed by Tislelizumab and CAPOX for Neoadjuvant Treatment of Locally Advanced Low Rectal Cancer: A Randomized Controlled Trial

Recruiting·RRuijin Hospital·Phase 2·NCT07888309·50 enrolled

A Prospective Single-Center Observational Study Evaluating Concordance Between Large Language Model-Generated Recommendations and Multidisciplinary Team Recommendations in Rectal Cancer

Recruiting·SShandong Cancer Hospital and Institute·N/A·NCT07595107·180 enrolled

Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial

Recruiting·SShandong Cancer Hospital and Institute·Phase 3·NCT06850090·210 enrolled

Multicentre, Prospective, Open-label Feasibility Study of Radiotherapy Dose Escalation for the Non-operative Management of Patients With Unresectable Locally Recurrent Rectal Cancer

Recruiting·—·Preclinical·NCT07721181·30 enrolled

Stigma and Psychological profilE in REctal-anal caNcer pAtients

Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·N/A·NCT06366841·148 enrolled

Radiochemotherapy With Concomitant Deep Regional Hyperthermia in Locally Advanced Rectal Cancer. A Prospective, Randomized Phase III Trial.

Recruiting·UUniversity Hospital Tuebingen·Preclinical·NCT06831981·264 enrolled

PATHWAYS: An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer

Recruiting·MMassachusetts General Hospital·Preclinical·NCT05914766·80 enrolled

Page 1 of 30

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)